Official Title
Phase II Study of Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis
Brief Summary

The administration of low-dose lung irradiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response. The present study will evaluate the efficacy of treatment with low-dose pulmonary radiotherapy added to standard support therapy, in hospitalized patients with respiratory symptoms due to COVID-19 pneumonia, who do not experience improvement with conventional medical therapy and are not subsidiaries of ICU

Detailed Description

The WHO has officially confirmed that: "Currently, there is no specific pharmacological

available treatment for COVID-19".

Beyond vital support, there are not currently treatment options for Coronavirus disease

(COVID-19) and related pneumonia, the infection caused by Severe Acute Respiratory Syndrome

Coronavirus 2 (SARS-CoV-2). Pulmonary irradiation is an option for the treatment of COVID-19

pneumonia and could be available quickly and with a duration of about 15 minutes of


Thoracic irradiation therapy at very low doses (0.5-1.0 Gy) dates back to the 1920s and was

the only effective mean to treat certain infectious and inflammatory diseases prior to the

development of antimicrobial therapies in the 1940s.

The goal is to replicate low-dose radiation therapy, just as it was used 80 years ago for

viral pneumonia with great success. It will be administered for a new disease, pneumonia

caused by COVID-19, for which there is no cure and many people are dying, mainly from severe

acute respiratory syndrome leading to very severe hypoxemic acute respiratory failure

refractory to treatment.

This therapy is expected to remedy acute respiratory syndrome by reducing inflammation, and

it also has a low risk of side effects and toxicities, given the low doses received, more

than one hundred times lower, compared to the usual radiotherapy used to tumor treatment.

Pneumonia, Viral

Radiation: Lung Low Dose Radiation
The administration of low-dose lung radiation produces anti-inflammatory effects that will decrease the pulmonary inflammatory response.

Eligibility Criteria

Inclusion Criteria: - Patients over 65 years old - Hospitalized with COVID-19 positive not subsidiary of ICU with severe disease defined by the presence of ALL the following characteristics: - Presence of unilateral or bilateral pulmonary infiltrates in chest X-ray or computed tomography (CT). - Acute respiratory failure expressed by PaO2 / FIO2

Eligibility Gender
Eligibility Age
Minimum: 65 Years

Francisco Garcia Piñón, MSc

Carlos Ferrer Albiach, MD
Principal Investigator
Hospital Provincial de Castellon

Hospital Provincial de Castellon
NCT Number
COVID-19 pneumonia
Low Dose Radiotherapy
MeSH Terms
Pneumonia, Viral